Issue
Korean Journal of Chemical Engineering,
Vol.26, No.4, 1090-1093, 2009
Characterization of solvent induced crystalline and amorphous homoharringtonine
The morphologies of homoharringtonine were conveniently controlled by solvent treatment and the morphologies of homoharringtonine were characterized by XRD and SEM. Crystalline homoharringtonine was simply made by dissolving homoharringtonine in a special polar solvent containing a small amount of water (methanol/water=98/2, v/v). On the other hand, amorphous homoharringtonine was made by dissolving homoharringtonine in relatively non-polar solvent (methylene chloride/methanol=98/2, v/v). Amorphous homoharringtonine, with a fine particle size, was obtained by dissolving in methylene chloride/methanol (98/2, v/v), following by spray drying. Also, residual solvents, methanol and methylene chloride, were easily removed to less than concentration limit in ICH (International Conference on Harmonisation) guidance by spray drying and successive drying in a vacuum oven. Amorphous homoharringtonine was more soluble in water than crystalline homoharringtonine, and the water content of amorphous homoharringtonine was less changeable than crystalline homoharringtonine at given humidity (95 RH%) during storage. This information is very useful for production and quality control of pharmaceuticals in the commercialization step.
[References]
  1. Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M, J. Natl. Cancer Inst., 80, 1095, 1988
  2. He J, Cheung AP, Wang E, Struble E, Fang K, Nguyen N, Liu P, J. Pharm. Biomed. Anal., 22, 541, 2000
  3. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL, Leukemia, 3, 1361, 2006
  4. Xie WZ, Lin MF, Huang H, Cai Z, Am. J. Chin. Med., 34, 233, 2006
  5. Luo CY, Tang JY, Wang YP, Hematology, 9, 259, 2004
  6. Zhou DC, Zittoun R, Marie JP, Bull. Cancer, 82, 987, 1995
  7. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF, Cancer, 103, 1850, 2005
  8. Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S, Leukemia, 11, 624, 1997
  9. O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM, Cancer, 98, 888, 2003
  10. Efferth T, Davey M, Olbrich A, Rucker G, Gebhart E, Davey R, Blood Cells Mol. Dis., 28, 160, 2002
  11. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O’Brien SM, Cancer, 15, 1591, 2001
  12. Keller L, Dumas F, d’Angelo J, Tetrahedron Lett., 42, 1911, 2001
  13. Kim BS, Kim JH, Korean J. Chem. Eng., 25(1), 108, 2008
  14. Chiou WL, Riegelman S, J. Pharm. Sci., 60, 1281, 1971
  15. Kim JH, Korean J. Biotechnol. Bioeng., 21, 1, 2006
  16. Park SS, Kang HY, Korean J. Chem. Eng., 25(1), 78, 2008
  17. Sharma US, Baulausbramanaian SV, Straubinger RM, J. Pharm. Sci., 84, 1223, 1995
  18. ICH guidance Q3C impurities: Residual solvents, Federal register, 62(247), 67378, 1997
  19. Hancock BC, Parks M, Pharm. Res., 17, 397, 2000
  20. Gi US, Min B, Lee JH, Kim JH, Korean J. Chem. Eng., 21(4), 816, 2004